Abstract
Bendamustine is a novel bifunctional chemotherapeutic agent with activity against multiple cancers. There has been no definitive data on its capacity to penetrate the central nervous system. Our chemoinformatic screening predicted excellent CNS penetration, which was validated by in vivo pharmacokinetic analysis in mice. Bendamustine has 35% CNS penetration in our mouse model. Bendamustine should be further evaluated for use in treatment of primary and secondary CNS tumors.
Original language | English (US) |
---|---|
Pages (from-to) | 1526-1530 |
Number of pages | 5 |
Journal | MedChemComm |
Volume | 3 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2012 |
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry